Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-08-26

Clinical Trial Update: Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating melatonin to reduce delirium in end-of-life patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Melatonin (melatonin)

Snippet

Sponsor: Fraser Health | Conditions: Delirium | Phase 3 | Status: COMPLETED